Form 4: Dynavax Technologies Director Lauren P Silvernail Reports Stock Option Grant and Restricted Stock Unit Award

Director Lauren P Silvernail reports the acquisition of stock options and restricted stock units in Dynavax Technologies Corp.

Summary

• On February 3, 2025, Lauren P Silvernail, a director of Dynavax Technologies Corp, was granted 42,750 stock options and 8,636 restricted stock units (RSUs).
• The stock options have an exercise price of $12.94 and vest over three years, with 1/3 vesting annually starting February 3, 2025, contingent upon continued service to the company, and expire on February 2, 2032.
• Each RSU represents a contingent right to receive one share of common stock and also vests over three years, with 1/3 vesting annually starting February 3, 2025, contingent upon continued service to the company.
• The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it incentivizes the director.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages continued service to the company.

Future Outlook

The vesting of the stock options and RSUs is contingent upon the reporting person's continued service to the company.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• Vesting schedules, such as the three-year annual vesting described in the document, are typical to ensure long-term commitment.
• Companies like Moderna, BioNTech, and Novavax also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants positively as they align the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates

Keywords

Dynavax Technologies, Director, Stock Options, Restricted Stock Units, RSU, DVAX, Form 4, Beneficial Ownership